Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price12.36 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-08-11Read Markup11.10+11.4% to today ✓Distribution gives way to Markup after a 21% rise in 6 weeks
2026-07-02Read Distribution9.20+34.3% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
RE/MAX Holdings Inc holds its Markup at $12.36. Consolidating, no directional conviction, held for 27 days.
As held on the ledger · 2026-08-24
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 27 days
Price at the screen
$12.36
Valuation
618.00 trailing · 8.66 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.83
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
78.88%
Below 33%
Interest-bearing debt is 78.9% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
25.01%
Below 49%
Money owed to the company is 25.0% of assets, under the 49% limit.
Pass
Revenue purity
1.23%
Below 5%
Only 1.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
RE/MAX's business is in a permissible area, but its interest-bearing debt is about 79% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RMAX's ethical verdict changes
Today RMAX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Listed by BDS Movement for: Markets and sells property in settlements built on Palestinian land. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Its inputs are 75 days old. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RMAX trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$12.36+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markup$12.36+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$12.36+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$12.36+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$12.36+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$12.36+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$12.36+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$12.36+0.0%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markup$12.36+0.0%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-10-02Markup$12.36+11.4%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $11. Since the last review it its composite score eased.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.